A survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.
A nulliparous woman, age 25 years, had received a diagnosis of non-Hodgkin lymphoma and now presented with stage IIA diffuse large B-cell lymphoma. Due to potential risks of chemotherapy-induced gonadotoxicity and subsequent iatrogenic premature ovarian failure and fertility loss, the patient was referred to the reproductive medicine department for fertility preservation counseling and further management.
According to Ronan J. Kelly, MD, MBA, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
In this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.
This segment examines Dr. Mikhael's approach to comparing ide-cel and cilta-cel for patient selection, emphasizing how patient traits, efficacy, and safety profiles influence treatment decisions across different groups.
Panelists discuss how the use of CAR T-cell therapy in earlier lines of treatment for relapsed/refractory multiple myeloma could potentially improve long-term outcomes, considering factors such as patient selection, optimal timing, and the impact on subsequent treatment options.
The panel shares some final thoughts on unmet needs and the future of CLL treatment.
Panelists discuss how successful implementation of chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (R/R MM) depends on early referral, coordinated care between academic and community centers, standardized protocols for patient management, and careful consideration of product selection and timing based on individual patient factors.
Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.
A rare case of spinal atypical teratoid/rhabdoid tumor is presented in an adult man after presenting with neck pain and bilateral upper extremity paralysis.
Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
Pallawi Torka, MD, and the Oncology Brothers discuss the therapeutic landscape for patients with relapsed/refractory mantle cell lymphoma.
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
The panel closes by highlighting currently unmet needs in the treatment and management of metastatic colorectal cancer.
Syed Arslan Shehzad Shah, MD, and colleagues present findings from a broad investigation into this rare neoplasm of the kidney, including data on patient demographics and mean survival.
Nationwide Circulating-Tumor DNA–Guided Basket and Umbrella Clinical Trials for Patients With Advanced Solid Tumors (GOZILA; UMIN000029315)